BCR and leukemia: For instance, tyrosine kinase inhibitors (TKIs) are used to treat leukemia with a BCR-ABL fusion gene, and abnormally spliced mRNA precursors after BCR-ABL transcription are often found that lack the target domain of TKIs and allow tumor cells to escape killing by drugs (17, 18).